Search Page

1

Cite

Share

Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).

Whiteside TL. Whiteside TL. Biochem Soc Trans. 2013 Feb 1;41(1):245-51. doi: 10.1042/BST20120265. Biochem Soc Trans. 2013. PMID: 23356291 Free PMC article. Review.

Cite

Share

2

Cite

Share

The tumor microenvironment and its role in promoting tumor growth.

Whiteside TL. Whiteside TL. Oncogene. 2008 Oct 6;27(45):5904-12. doi: 10.1038/onc.2008.271. Oncogene. 2008. PMID: 18836471 Free PMC article. Review.

Cite

Share

3

Cite

Share

Immunotherapy of cancer in 2012.

Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Kirkwood JM, et al. CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. CA Cancer J Clin. 2012. PMID: 22576456 Free PMC article. Review.

Cite

Share

4

Cite

Share

Immune responses to malignancies.

Whiteside TL. Whiteside TL. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83. doi: 10.1016/j.jaci.2009.09.045. Epub 2010 Jan 12. J Allergy Clin Immunol. 2010. PMID: 20061007 Free PMC article. Review.

Cite

Share

5

Cite

Share

Update on vaccine development for renal cell cancer.

Chi N, Maranchie JK, Appleman LJ, Storkus WJ. Chi N, et al. Open Access J Urol. 2010 Aug 4;2:125-41. doi: 10.2147/rru.s7242. Open Access J Urol. 2010. PMID: 24198621 Free PMC article. Review.

Cite

Share

6

Cite

Share

Soluble HLA-G: Are they clinically relevant?

Pistoia V, Morandi F, Wang X, Ferrone S. Pistoia V, et al. Semin Cancer Biol. 2007 Dec;17(6):469-79. doi: 10.1016/j.semcancer.2007.07.004. Epub 2007 Jul 31. Semin Cancer Biol. 2007. PMID: 17825579 Free PMC article. Review.

Cite

Share

7

Cite

Share

Induced and natural regulatory T cells in human cancer.

Whiteside TL, Schuler P, Schilling B. Whiteside TL, et al. Expert Opin Biol Ther. 2012 Oct;12(10):1383-97. doi: 10.1517/14712598.2012.707184. Epub 2012 Jul 31. Expert Opin Biol Ther. 2012. PMID: 22849383 Free PMC article. Review.

Cite

Share

8

Cite

Share

Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Whiteside TL. Whiteside TL. Expert Opin Biol Ther. 2010 Jul;10(7):1019-35. doi: 10.1517/14712598.2010.482207. Expert Opin Biol Ther. 2010. PMID: 20415597 Free PMC article. Review.

Cite

Share

9

Cite

Share

Integrating costimulatory agonists to optimize immune-based cancer therapies.

Pardee AD, Wesa AK, Storkus WJ. Pardee AD, et al. Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Immunotherapy. 2009. PMID: 20046961 Free PMC article. Review.

Cite

Share

10

Cite

Share

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. Price MA, et al. Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57. doi: 10.1111/j.1755-148X.2011.00929.x. Pigment Cell Melanoma Res. 2011. PMID: 22004131 Free PMC article. Review.

Cite

Share